Search

everythinglearnresearchcommunity

for

Search:↓

An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.

IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.

The PIRL laser cuts tissue with less damage and scarring than traditional methods.

The LTF gene may help predict and manage nonspecific orbital inflammation.

LLPS is crucial for RALF signaling, aiding plant growth and stress resilience.

LONRF1 is important for oxidative damage response and tissue remodeling during wound healing.

The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.

Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Low-level laser therapy reduces symptoms and inflammation in frontal fibrosing alopecia.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

miR-203a-3p helps hair follicle stem cells become specialized by targeting Smad1.

Researchers found a new genetic mutation linked to a hair condition in a Japanese boy.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

miR‑339‑5p can slow down hair follicle stem cell differentiation by targeting DLX5.

FLCN helps control iron levels in cells.

Loricrin affects skin immune function and homeostasis.

Injectable platelet-rich fibrin improves hair growth and reduces hair loss in women.

Targeting Hedgehog signaling may help treat ligamentum flavum fibrosis.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Researchers found a new mutation in the LIPH gene of a woman with a rare hair condition.

Monitoring TGF-β and linc-PINT expression may help identify and treat high-risk heart arrhythmia patients.

QLT0267 stops hair follicle cell growth and movement.

IL-3 worsens lupus nephritis and blocking it improves kidney health.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.